Surf Therapeutics, a clinical-stage company developing non-invasive ultrasound neuromodulation therapies for immune-mediated diseases, has closed an extension seed financing round. This brings their total funding to approximately $6 million. The company recently announced positive first-in-human study results for their novel treatment approach.
